key: cord-0739891-89y4mpuq authors: Rodriguez-Nava, Guillermo; Shrestha, Ekta; Upadhyay, Binayak; Morante, Aldo; Joseph, Deepa; Suhail, Aimen; Trelles-Garcia, Daniela Patricia; Yanez-Bello, Maria Adriana title: Bleeding pneumonia: diffuse alveolar hemorrhage due to human metapneumovirus date: 2020-06-30 journal: IDCases DOI: 10.1016/j.idcr.2020.e00894 sha: c6bf6d914aa1e261cfdf618442cf5f4ff1d5ae34 doc_id: 739891 cord_uid: 89y4mpuq Diffuse alveolar hemorrhage is a condition with high morbidity and mortality. The majority of cases are caused by pulmonary capillaritis associated with systemic vasculitis. Infection disease has also been associated with this condition. A 62-year-old woman with a history of chronic alcohol abuse presented with shortness of breath, hemoptysis, constipation, and icterus. Chest x-rays on admission showed diffuse patchy opacities concerning for diffuse alveolar hemorrhage. The patient quickly developed acute respiratory failure requiring intubation. PCR identified human metapneumovirus and bronchoalveolar lavage confirmed alveolar hemorrhage. Despite all efforts, the patient ultimately developed multi-organ failure and died. Human metapneumovirus is usually associated with mild upper and lower respiratory tract infections in young children. Nevertheless, clinicians should recognize that this virus has recently emerged as a significant pathogen, particularly in adult patients with underlying conditions and the elderly population. Diffuse alveolar hemorrhage (DAH) is a catastrophic clinical syndrome potentially leading to respiratory failure [1] . It usually presents with hemoptysis, anemia, and diffuse alveolar infiltrates, but the findings are nonspecific [1, 2] . Despite advances in the identification and management of DAH, mortality remains high ranging from 30% to 100%, depending on the underlying etiology [1] . Early recognition is crucial as prompt diagnosis and treatment increase the chances of survival [2] . Up to 88% of the cases of DAH are caused by pulmonary capillaritis associated with systemic vasculitis [1, 2] . In immunocompetent patients, lung infections are rarely reported as the etiology of DAH [3] . Human metapneumovirus (hMPV) mostly causes upper and lower respiratory tract infections in young children. Still, it is also a common unidentified trigger in adult patients with asthma and chronic obstructive pulmonary disease (COPD) [4, 5] . Lethal hMPV infections in adults J o u r n a l P r e -p r o o f have been classically described in immunosuppressed patients [6] . We present a case of DAH secondary to human metapneumovirus infection in the setting of end-stage liver disease. A 62-year-old woman with no known past medical history presented on February 23, 2020, with sudden onset shortness of breath at rest for one week associated with hemoptysis. On interrogation, she referred intermittent yellow sclera for one month, and her son mentioned heavy alcohol consumption. She migrated from Mexico more than 30 years ago and was never in contact with a known tuberculosis case. Given her illegal alien immigrant status, she had limited access to health care and had no regular follow-ups with primary care physicians. On presentation in the emergency department, she was tachypneic and tachycardiac with significant respiratory distress. She was placed on a nonrebreather mask, started on broad-spectrum antibiotic therapy as per sepsis protocol, and transferred to a progressive care unit (PCU). In the PCU, she was further upgraded to bilevel positive airway pressure. Her exam was significant for scleral icterus and dried blood on lips and chin, diffuse crackles over bilateral lower lung fields, and bilateral lower extremity pitting edema. Initial lab results showed a white blood cell count of 25.7 k/mm 3 (4.0 -11.0 k/mm 3 ), (COVID-19) testing, but the request was denied as the patient did not meet the criteria for trial at that point. She had no history of recent travels, no sick contacts, and community transmission was not suspected in the State of Illinois at that time. On admission day 4, she was started on vasopressors due to shock. On day eight, she was placed in a prone position for 24 hours due to worsening hypoxia. On days 9 and 10, she required hemodialysis for severe acute kidney injury (creatinine 4.83 mg/dL) with acidosis (pH 7.21). On day 11 she developed disseminated intravascular coagulation (platelet count k/mm 3 , D-dimer 36,469 ng/mL and fibrinogen 91 mg/dL). CT head without contrast showed scattered small bilateral subarachnoid hemorrhages. She ultimately developed multi-organ failure, had a cardiac arrest, and was declared dead after unsuccessful attempts at resuscitation. Diffuse alveolar hemorrhage is a critical condition that presents with hemoptysis, anemia, diffuse radiographic pulmonary infiltrates, and hypoxemic respiratory failure [1, 2] . DAH is characterized by the accumulation of intra-alveolar red blood cells originating from the bronchial vessels, the pulmonary vessels, or the microcirculation [1] [2] [3] . Bronchoscopy with bronchoalveolar lavage is the gold standard to confirm the diagnosis. Systemic autoimmune diseases such as anti-neutrophil cytoplasmic antibody-associated vasculitis, anti-glomerular basement membrane disease, and systemic lupus erythematosus, represent the most common cause of capillaritis associated with DAH. Although rare in immunocompetent patients, lung infections can also cause alveolar microcirculation injury, J o u r n a l P r e -p r o o f secondary to generalized or lung-specific disease, and DAH [2, 3] . In our patient, likely the presence of chronic alcoholism, unmanaged end-stage liver disease, decompensated liver cirrhosis, and hence baseline predisposition for bleeding diastasis played an essential role in the development of infectious DAH. Human metapneumovirus is an enveloped, non-segmented, negative-sense, singlestranded RNA virus [7] . It belongs to the order Mononegavirales in the family Paramyxoviridae, and it was the first human member of the Metapneumovirus genus in the subfamily Pneumovirinae of the family Paramyxoviridae [7, 8] . Since its discovery, hMPV has been isolated on all continents and has a seasonal distribution, with outbreaks primarily occurring in the spring and winter months and accounting for up to 11% of respiratory tract infections [4, 5] . It is thought to be transmitted by direct or close contact with contaminated secretions, which may involve saliva, droplets, or large particle aerosols. It has an incubation period of 5 to 9 days, with a median of 5 days [9] . In general terms, hMPV infection cannot be distinguished from other respiratory viruses, and symptoms include fever, cough, rhinorrhea, and wheezing [5, 9] . The severity of the illness varies considerably, from asymptomatic carriers to acute respiratory distress syndrome. Severe disease has been mainly described in children, elderly and immunocompromised patients with underlying conditions, including asthma, cancer, and COPD [6, 8, 10] . DAH is an uncommon manifestation of severe hMPV infection in otherwise immunocompetent patients, in which the more common pathogens include influenza A (H1N1), dengue, leptospirosis, malaria, and Staphylococcus aureus infection [3]. hMPV should be considered an emerging respiratory pathogen with a significant burden of disease in adults. In a population-based surveillance study in the United States (US) by Jain [11] , hMPV was isolated as a single pathogen in 4% of hospitalized adults with community-acquired pneumonia. In one retrospective study by Hasvold [5] , 31% of hospitalized patients with hMPV infection required ICU admission, and 48% of those J o u r n a l P r e -p r o o f 8 patients met the criteria for ARDS. Furthermore, the latest data available from the CDC WONDER mortality database show that 72.6% of the reported deaths in the US since 2011 from hMPV pneumonia or bronchiolitis (ICD-10 codes J12.3 and J21.1, respectively) occurred from 2016 onwards, the vast majority in patients 65 years old or older (45.3%) [12] . Management of hMPV infection is primarily supportive care as there is no standard treatment; however, promising therapy with intravenous (IV) ribavirin and IV immunoglobulin (IVIG) has been reported [13] . Ribavirin is a nucleoside with activity against RNA viruses that have shown in vitro activity against hMPV and exhibited some efficacy in animal models and case series [8, 9, 13] . Commercial IVIG contains neutralizing action against hMPV that also has demonstrated prophylactic and therapeutic efficacy in animal models and case series [8, 13] . Most important, droplet respiratory precautions must be applied to prevent nosocomial transmission of this pathogen. Lethal hMPV infections in adults have been classically described in immunosuppressed patients. Nevertheless, in recent years this pathogen has emerged as a significant respiratory virus that carries high morbidity and mortality, especially in the elderly population. Lower respiratory tract infections are rarely reported in association with DAH, but they should be considered in the differential diagnosis because of the therapeutic implications. All persons who meet authorship criteria are listed as authors, and all authors certify that they have participated sufficiently in this work to take public responsibility for the content, including participation in the concept, design, analysis, writing, or revision of the manuscript. Furthermore, each author certifies that this material or similar material has not been and will not be submitted to or published in any other publication. Written informed consent was obtained from the patient's next-of-kin for publication of this case report. A copy of the written consent is available for review by the Editor of this journal. Our institution does not require ethical approval for case reports This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors declared no conflict of interest. J o u r n a l P r e -p r o o f Diffuse alveolar hemorrhage Diffuse alveolar hemorrhage Infectious diseases causing diffuse alveolar hemorrhage in immunocompetent patients: a state-of-the-art review Human metapneumovirus: review of an important respiratory pathogen The role of human metapneumovirus in the critically ill adult patient A prospective study comparing human metapneumovirus with other respiratory viruses in adults with hematologic malignancies and respiratory tract infections Human Metapneumovirus: lessons learned over the first decade Human metapneumovirus -what we know now Human metapneumovirus in adults Burden of human metapneumovirus infection in young children Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults Underlying Cause of Death 1999-2018 on CDC WONDER Online Database, released in 2020. Data are from the Multiple Cause of Death Files, 1999-2018, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program The human metapneumovirus: a case series and review of the literature To our respiratory therapist, who make our work in the Intensive Care Unit much easier.J o u r n a l P r e -p r o o f